You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
iRhythm Holdings, Inc. adopted the iRhythm Deferred Compensation Plan, effective January 1, 2027, allowing eligible employees to defer up to 80% of base salary and 100% of annual bonuses, and directors to defer 100% of cash fees.
iRhythm reported third-quarter revenue of $221.6 million, up 14.9% year-over-year, and raised 2026 revenue guidance to $890 million to $895 million. It shifted the Zio MCT FDA submission to 2027 to prioritize Vital Connect integration.
iRhythm reported third-quarter 2026 revenue of $221.6 million, up 14.9%, and raised 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0%. It completed the VitalConnect acquisition on October 5, 2026.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. iRhythm reported Q2 2026 revenue of $224.2M (+20.1% YoY) with adjusted EBITDA margin of 19.3% (+1,090 bps) and raised full-year 2026 revenue guidance to $880M-$890M and adjusted EBITDA margin guidance to 13.0%-14.0%, while announcing a $287.5M acquisition of Vital Connect to expand into MCT and multi-vitals monitoring.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $43.3M | Second Quarter 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss, as reported -$381K
+$3.29M Interest expense
-$4.78M Interest income
-$822K Changes in fair value of strategic investments
+$0K Income tax provision (benefit)
+$5.22M Depreciation and amortization
+$20.04M Stock-based compensation
+$0K Impairment charges
+$1.16M Business transformation costs
+$4.93M Intellectual property litigation expenses
+$13.95M Litigation settlements
+$686K Cybersecurity incident
= Adjusted EBITDA $43.3M
|
|||
| Adjusted EBITDA margin non-GAAP | 19.3% | Second Quarter 2026 | — |
| Adjusted net income non-GAAP | $19.3M | Second Quarter 2026 | — |
| Adjusted operating expenses non-GAAP | $145M | Second Quarter 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating expenses, as reported $165.75M
+$0K Impairment charges
-$1.16M Business transformation costs
-$4.93M Intellectual property litigation expenses
-$13.95M Litigation settlements
-$686K Cybersecurity incident
= Adjusted operating expenses $145.03M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IRTC
this stock
iRhythm Holdings, Inc.
|
$3.09B | -48.2% | +26.2% | — | 9.7% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
iRhythm Holdings, Inc. adopted the iRhythm Deferred Compensation Plan, effective January 1, 2027, allowing eligible employees to defer up to 80% of base salary and 100% of annual bonuses, and directors to defer 100% of cash fees.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IRTC | +1.9% | -15.4% | -19.7% | -25.5% | -48.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -0.7% | -14.3% | -20.2% | -25.3% | -58.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
